200 related articles for article (PubMed ID: 30247101)
1. Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.
Merola D; Yong C; Noga SJ; Shermock KM
J Manag Care Spec Pharm; 2018 Oct; 24(10):1019-1026. PubMed ID: 30247101
[TBL] [Abstract][Full Text] [Related]
2. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation.
Parasuraman S; Thiel E; Park J; Teschemaker A
J Med Econ; 2023; 26(1):454-462. PubMed ID: 36883994
[TBL] [Abstract][Full Text] [Related]
3. Indirect costs associated with metastatic breast cancer.
Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L
J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016
[TBL] [Abstract][Full Text] [Related]
4. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study.
Feldman SR; Zhao Y; Gilloteau I; Graham CN; Miles L; McBride D; Herrera V
J Manag Care Spec Pharm; 2018 Jul; 24(7):617-622. PubMed ID: 29952701
[TBL] [Abstract][Full Text] [Related]
5. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
6. Workplace Productivity Loss and Indirect Costs Associated With Preterm Birth in the United States.
Patel VP; Davis M; Li J; Hwang S; Johnson S; Kondejewski J; Croft D; Rood K; Simhan HN
Obstet Gynecol; 2024 Jan; 143(1):23-34. PubMed ID: 37851518
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
8. Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study.
Cong Z; Tran O; Nelson J; Silver M; Chung K
Appl Health Econ Health Policy; 2022 Nov; 20(6):845-856. PubMed ID: 36040661
[TBL] [Abstract][Full Text] [Related]
9. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
10. The economic impact of bipolar disorder in an employed population from an employer perspective.
Gardner HH; Kleinman NL; Brook RA; Rajagopalan K; Brizee TJ; Smeeding JE
J Clin Psychiatry; 2006 Aug; 67(8):1209-18. PubMed ID: 16965198
[TBL] [Abstract][Full Text] [Related]
11. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States.
Patel JG; Nagar SP; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2014; 9():289-300. PubMed ID: 24672234
[TBL] [Abstract][Full Text] [Related]
12. Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures.
Song X; Quek RG; Gandra SR; Cappell KA; Fowler R; Cong Z
BMC Health Serv Res; 2015 Jun; 15():245. PubMed ID: 26104784
[TBL] [Abstract][Full Text] [Related]
13. Indirect and direct costs of acute coronary syndromes with comorbid atrial fibrillation, heart failure, or both.
Ghushchyan V; Nair KV; Page RL
Vasc Health Risk Manag; 2015; 11():25-34. PubMed ID: 25565859
[TBL] [Abstract][Full Text] [Related]
14. Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine.
Gilligan AM; Foster SA; Sainski-Nguyen A; Sedgley R; Smith D; Morrow P
J Occup Environ Med; 2018 Dec; 60(12):1120-1127. PubMed ID: 30199470
[TBL] [Abstract][Full Text] [Related]
15. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.
Ivanova JI; Birnbaum HG; Samuels S; Davis M; Phillips AL; Meletiche D
Pharmacoeconomics; 2009; 27(8):681-91. PubMed ID: 19712010
[TBL] [Abstract][Full Text] [Related]
16. Estimating the Societal Benefits of THA After Accounting for Work Status and Productivity: A Markov Model Approach.
Koenig L; Zhang Q; Austin MS; Demiralp B; Fehring TK; Feng C; Mather RC; Nguyen JT; Saavoss A; Springer BD; Yates AJ
Clin Orthop Relat Res; 2016 Dec; 474(12):2645-2654. PubMed ID: 27699631
[TBL] [Abstract][Full Text] [Related]
17. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
18. Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.
Yu JS; Hansen RN; Valderrama A; Carlson JJ
Leuk Lymphoma; 2016 Nov; 57(11):2636-43. PubMed ID: 27077242
[TBL] [Abstract][Full Text] [Related]
19. Health and disability costs of depressive illness in a major U.S. corporation.
Druss BG; Rosenheck RA; Sledge WH
Am J Psychiatry; 2000 Aug; 157(8):1274-8. PubMed ID: 10910790
[TBL] [Abstract][Full Text] [Related]
20. Productivity loss by cancer stage in patients newly diagnosed with hepatocellular carcinoma: A claims database analysis.
Cheng SJ; Bansal A; Veenstra DL
J Manag Care Spec Pharm; 2024 Jun; 30(6):572-580. PubMed ID: 38824631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
